HERG Screening Market Analysis Through 2030: Market Size, Growth Trends And Industry Outlook
Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
HERG Screening Market Set To Climb From $2.06 Billion In 2026 To $3.2 Billion By 2030
The herg screening market has experienced substantial expansion in recent times. Its valuation is projected to increase from $1.84 billion in 2025 to $2.06 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 12.0%. This historical expansion is attributable to several factors, including an uptick in cardiac-related drug withdrawals, greater investment in preclinical safety studies, the flourishing of pharmaceutical R&D, the adoption of in-vitro ion channel assays, and enhanced understanding of drug-induced arrhythmias.
The herg screening market is poised for significant growth in the upcoming years. It is forecast to achieve a valuation of $3.21 billion in 2030, demonstrating a compound annual growth rate (CAGR) of 11.7%. This expansion during the projection period can be credited to advances in AI-driven predictive toxicology, the adoption of organ-on-chip technologies, the increasing development of biologics and personalized medicine, a surge in outsourcing to CDMOs, and the expansion of preclinical research in emerging markets. Prominent trends anticipated in this period include enhanced cardiotoxicity modeling, automated high-throughput screening, the incorporation of predictive analytics in preclinical safety evaluations, an increase in contract research services, and the application of miniaturized microfluidic assays.
Get A Free Sample Report With In-Depth Market Insights:
HERG Screening Market Expansion Drivers: What’s Shaping Future Growth?
The increasing number of patients diagnosed with heart disorders is projected to boost the expansion of the HERG screening market moving forward. Heart disorders, also termed cardiovascular disorders or diseases, describe various conditions affecting the heart and blood vessels. These ailments can compromise the heart’s proper function and potentially lead to serious health complications. Such disorders stem from factors like unhealthy lifestyles, an aging demographic, genetic predispositions, diabetes, and metabolic syndrome. HERG screening assists in identifying promising drug candidates, preventing adverse cardiac events that could provoke life-threatening cardiac arrhythmias, particularly torsade de pointes (TdP), and improving patient outcomes. For instance, in October 2025, the Australian Institute of Health and Welfare, an Australia-based government agency, reported that in 2023, an estimated 57,100 adults aged 25 and above experienced acute coronary events, averaging approximately 156 incidents per day. Therefore, the growing incidence of patients with heart disorders is propelling the HERG screening market’s growth.
HERG Screening Market Segment Analysis: What Are The Core Market Categories?
The herg screening market covered in this report is segmented –
1) By Type: Gene KCNH2, Mutant KCNH2
2) By Ion Channel: Voltage-Gated, Ligand Gated
3) By Applications: Antiarrhythmic, Antipsychotic, Antibiotics, Other Applications
Subsegments:
1) By Gene KCNH2: Wild-Type KCNH2, Recombinant KCNH2
2) By Mutant KCNH2: Mutations: Missense Mutations, Nonsense Mutations, Frameshift Mutations
HERG Screening Market Strategic Trends: What Defines The Next Growth Phase?
Leading firms in the HERG screening market are concentrating on developing novel, advanced solutions, such as GLP-certified HERG screening services, to improve cardiac safety assessments during the drug development process. This particular service involves the good laboratory practice-certified screening of the human ether-à-go-go related gene (hERG) employing the traditional whole-cell patch-clamp technique. It ensures adherence to regulatory guidelines like ICH S7A and ICH S7B, which are crucial for safety pharmacology studies within drug development. For instance, in August 2023, Metrion Biosciences Ltd., a pharmaceutical company based in the UK, introduced its good laboratory practice (GLP)-certified hERG screening service. This offering aims to strengthen Metrion’s support for the development of small-molecule therapeutics and expand its existing portfolio of cardiac safety services. Furthermore, this service leverages the conventional whole-cell patch-clamp technique to evaluate potential cardiac liabilities before human subjects enter Phase 1 clinical trials, provides regulatory advice for safety pharmacology studies in drug development, and delivers high-quality biology services to clients targeting ion channels.
HERG Screening Market Top Companies Driving Competitive Growth
Major companies operating in the herg screening market are Eurofins-Cerep SA, Aviva Biosciences Inc., AstraZeneca Public Limited Company, Merck KGaA, Charles River Laboratories Inc., Abcam Public Limited Company, Molecular Devices LLC, Caliper Life Sciences Inc., ChanTest Corporation, Creative Bioarray Inc., Cellular Dynamics International Inc., Nanion Technologies, Essen Bioscience, ACEA Biosciences Inc., Metrion Biosciences Inc., Aurora Biomed Inc., Aureus Sciences, RedShift BioAnalytics, Sophion Bioscience Inc., Fluxion Biosciences Inc.
View The Full HERG Screening Market Report:
HERG Screening Market Geographic Landscape: Which Region Dominates Industry Growth?
North America was the largest region in the HERG screening market in 2025. Asia-Pacific is expected to be the fastest growing region in the forecast period. The regions covered in the herg screening market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
